- Home
- KITT vs ACRV Comparison
KITT vs ACRV Comparison
Compare KITT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KITT
- ACRV
- Stock Information
- Founded
- KITT 2014
- ACRV 2018
- Country
- KITT United States
- ACRV United States
- Employees
- KITT N/A
- ACRV N/A
- Industry
- KITT Industrial Machinery/Components
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- KITT Industrials
- ACRV Health Care
- Exchange
- KITT Nasdaq
- ACRV Nasdaq
- Market Cap
- KITT 36.4M
- ACRV 47.8M
- IPO Year
- KITT N/A
- ACRV 2022
- Fundamental
- Price
- KITT $3.55
- ACRV $1.51
- Analyst Decision
- KITT
- ACRV Buy
- Analyst Count
- KITT 0
- ACRV 7
- Target Price
- KITT N/A
- ACRV $17.40
- AVG Volume (30 Days)
- KITT 407.1K
- ACRV 3.4M
- Earning Date
- KITT 11-11-2025
- ACRV 11-12-2025
- Dividend Yield
- KITT N/A
- ACRV N/A
- EPS Growth
- KITT N/A
- ACRV N/A
- EPS
- KITT N/A
- ACRV N/A
- Revenue
- KITT $3,082,232.00
- ACRV N/A
- Revenue This Year
- KITT $2,936.06
- ACRV N/A
- Revenue Next Year
- KITT N/A
- ACRV $805.34
- P/E Ratio
- KITT N/A
- ACRV N/A
- Revenue Growth
- KITT N/A
- ACRV N/A
- 52 Week Low
- KITT $3.33
- ACRV $1.05
- 52 Week High
- KITT $54.36
- ACRV $10.00
- Technical
- Relative Strength Index (RSI)
- KITT 26.21
- ACRV 55.47
- Support Level
- KITT $3.35
- ACRV $1.46
- Resistance Level
- KITT $3.72
- ACRV $2.67
- Average True Range (ATR)
- KITT 0.79
- ACRV 0.19
- MACD
- KITT -0.27
- ACRV 0.02
- Stochastic Oscillator
- KITT 3.82
- ACRV 14.96
About KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.